Welcome to our dedicated page for Compass Pathways news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways stock.
COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways (Nasdaq: CMPS) welcomed the White House Executive Order to accelerate psychedelic treatments for serious mental illness. Compass highlighted two positive phase 3 COMP360 trials in treatment-resistant depression (TRD) with >1,000 participants, rapid effects within one day and durability to six months.
The company is working on a rolling FDA submission for COMP360 in TRD and is starting a late-stage PTSD trial after IND clearance.
Compass Pathways (Nasdaq: CMPS) launched a U.S. grant program to fund creation of provider training for investigational COMP360 psilocybin treatment ahead of a potential commercial launch. Compass expects to award up to three grants. Applications open April 14–May 14, 2026 at training-grants.compasspathways.com.
The program targets established U.S. training organizations to build foundational psychedelic and COMP360-specific modules to support clinical readiness and consistent patient care if COMP360 is approved.
Compass Pathways (Nasdaq: CMPS) will attend the Needham Virtual Healthcare Conference on April 14, 2026 and participate in a fireside chat at 12:45 PM ET. A live audio webcast will be available on the company’s Investors "Events" page.
According to the company, a replay of the webcast will be accessible for 30 days following the event.
Compass Pathways (Nasdaq: CMPS) granted inducement equity awards to seven newly hired non-executive employees on April 1, 2026 under the 2026 Inducement Plan.
The awards include options covering an aggregate of 117,445 shares and restricted share units or nominal cost options covering 55,875 shares, at an exercise price of $5.62, vesting over four years per grant terms.
Compass Pathways (Nasdaq: CMPS) reported Q4 and full-year 2025 results and business highlights on March 24, 2026. Key points: COMP360 achieved positive Phase 3 results showing rapid onset and durability in treatment resistant depression, FDA meeting planned for rolling NDA review, IND accepted for PTSD Phase 2b/3, and recent financings extend cash runway into 2028.
Financials: net loss $287.9M for FY2025, cash $149.6M at Dec 31, 2025, and debt $31.6M (reported), with additional $50.4M debt noted as of March 24, 2026.
Compass Pathways (Nasdaq: CMPS) management will attend the Stifel 2026 Virtual CNS Forum on March 17-18, 2026 and will take part in a fireside chat on March 18, 2026 at 10:30am ET.
A live audio webcast will be available on the company’s Investors > Events page, with a replay accessible for 30 days following the event.
Compass Pathways (Nasdaq: CMPS) exercised 35,059,448 outstanding warrants on February 26, 2026, generating approximately $200 million in proceeds. The company issued 15,160,619 ADSs and, to certain institutional investors, pre-funded warrants to purchase up to 19,898,829 ADSs. Compass intends to use these proceeds, plus ~$141 million from a Feb 20, 2026 public offering and existing cash, to fund COMP005 and COMP006 Phase 3 trials, a Phase 2b/3 COMP360 PTSD trial, commercial readiness, and working capital; combined funds are expected to fund operations into 2028.
Compass Pathways (Nasdaq: CMPS) will attend the TD Cowen 46th Annual Healthcare Conference in Boston from March 2-4, 2026 and will hold a fireside chat on March 3, 2026 at 10:30am ET. A live audio webcast will be available on the company Investors "Events" page, with replays accessible for 30 days.
Compass Pathways (Nasdaq: CMPS) priced a public offering of 17,500,000 ADSs at $8.00 each and pre-funded warrants for up to 1,250,000 ADSs at $7.9999. Underwriters have a 30-day option for up to 2,812,500 ADSs. The offering is expected to close on or about February 20, 2026, with gross proceeds of approximately $150.0 million.
According to the company, net proceeds will fund ongoing COMP005 and COMP006 Phase 3 trials, a Phase 2b/3 trial of COMP360 in PTSD, accelerate commercial readiness, and support working capital and general corporate purposes.
Compass Pathways (Nasdaq: CMPS) launched a proposed public offering of $150.0 million of American Depositary Shares (ADSs) and, for certain institutional investors, pre-funded warrants. The company also expects to grant underwriters a 30-day option to buy up to an additional $22.5 million of ADSs.
The offering is subject to market conditions and will be made from a shelf registration effective May 7, 2025; a preliminary prospectus supplement will be filed with the SEC.